Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 28 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $1156.14, accompanied by a high estimate of $1300.00 and a low estimate of $895.00. Experiencing a 3.64% decline, the current average is now lower than the previous average price target of $1199.85.

Decoding Analyst Ratings: A Detailed Look

The standing of Regeneron Pharmaceuticals...